Arch Therapeutics extends note maturity to June 30, 2024 and broadens uplist definition

On April 30, 2024, the Company also entered into an amendment (" Amendment No. 2 to the Fourth Notes " and, together with Amendment No. 16 to the First Notes, Amendment No. 16 to the Second Notes and Amendment No. 11 to the Third Notes, the " Amendments to the Notes ") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on March 15, 2024, issued in connection with a private placement financing the Company completed on March 12, 2024 (as amended, the " Fourth Notes " and, together with the First Notes, Second Notes, and Third Notes, the " Notes ").

On April 30, 2024, the Company also entered into an amendment (" Amendment No. 16 to the Second Notes ") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on February 14, 2023, March 10, 2023, March 15, 2023, April 15, 2023, May 15, 2023, June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024 and March 15, 2024 (as amended, the " Second Notes "), issued in connection with a private placement financing the Company completed on January 18, 2023.

On May 1, 2024, the Company entered into an amendment (" Amendment No. 4 to the Bridge Registration Rights Agreement ") to that certain Registration Rights Agreement, dated as of July 7, 2023, as amended on August 30, 2023, and as subsequently amended on November 8, 2023 and November 21, 2023, by and among the Company and certain institutional and accredited individual investors (as amended the " Bridge Registration Rights Agreement ") in connection with a private placement offering of pre-funded warrants to purchase shares of Common Stock, common warrants to purchase shares of Common Stock, and shares of Common Stock. Under Amendment No. 4 to the Bridge Registration Rights Agreement, the Bridge Registration Rights Agreement was amended to redefine "Uplist" as the public offering of the Company's Common Stock pursuant to a registration statement on Form S-1 that results in the listing of the Company's Common Stock on any securities exchange registered with the SEC as a "national securi

On April 30, 2024, Arch Therapeutics, Inc. (the " Company ") entered into an amendment (" Amendment No. 1 to the Third A&R Registration Rights Agreement ") to that certain Third Amended and Restated Registration Rights Agreement, dated as of March 12, 2024, by and among us and certain institutional and accredited individual investors, as amended (the " A&R Registration Rights Agreement "). Under Amendment No. 1 to the Third A&R Registration Rights Agreement, the A&R Registration Rights Agreement was amended to redefine "Uplist Transaction" as the listing of the Company's common stock, par value $0.001 (" Common Stock "), on any securities exchange registered with the U.S. Securities and Exchange Commission (" SEC ") as a "national securities exchange" under Section 6 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ").

On April 30, 2024, the Company also entered into an amendment (" Amendment No. 11 to the Third Notes ") with the holders of the Company's outstanding Unsecured Convertible Promissory Notes, as separately amended on June 15, 2023, July 1, 2023, July 7, 2023, July 31, 2023, August 30, 2023, September 30, 2023, October 31, 2023, November 15, 2023, January 5, 2024 and March 15, 2024 (as amended, the " Third Notes "), issued in connection with a private placement financing the Company completed on May 15, 2023.